



**Brussels, 23 January 2017  
(OR. en)**

**5494/17**

**JAI 56  
CORDROGUE 6  
SAN 34**

## **OUTCOME OF PROCEEDINGS**

---

From: General Secretariat of the Council  
On: 11 and 12 January 2017  
To: Delegations

---

Subject: Outcome of the Horizontal Working Party on Drugs of 11-12 January 2017

---

### **1. Adoption of the agenda**

The meeting adopted the agenda as outlined in doc. CM 5240/16.

### **2. Implementation of the UNGASS outcome document and preparation for the 2019 review process**

The Presidency presented the draft EU statements for the forthcoming first CND intersessional meeting on 23-25 January 2016 on different chapters of the UNGASS outcome document. The revised statements taking on board delegations' comments from the meeting were issued during and after the HDG meeting for endorsement through the silence procedure. The need for increased national coordination between capital and Vienna delegates so as to ensure the smooth process of preparing the EU statements was emphasised.

Delegations finalised the discussion on the draft EU common position on post-UNGASS, contained in doc. WK 561/2016 REV 2. The EU common position was endorsed by the HDG and would be tabled for COREPER approval on 19 January 2017.

### **3. Preparation for the 60th CND session**

The UK presented a proposal for a CND resolution on new psychoactive substances contained in doc. WK 104/2017. Delegations welcomed the proposal, and the deadline of 13 January 2017 was set for providing written comments on this draft resolution with a view to discussing the revised version at the next HDG meeting.

The Presidency informed the meeting about the planned side event at the 60th CND session on alternatives to coercive sanctions. A number of delegations also informed the meeting about their plans to organise side events.

### **4. Information on the relevant international events**

The NL delegation informed delegations about the forthcoming WHO executive board meeting to be held in Geneva. The representative of the Commission gave an overview of the recent meeting on drugs with China, held together with the EEAS on 20 October 2016 back to back to the annual follow-up group meeting on drug precursors, during which new psychoactive substances were also extensively discussed. The representative of the EEAS informed the meeting that Iran expressed interest in cooperating more closely with the EU in the field of drugs. According to the speaker, Iran would be interested in learning from the EU experience in drug prevention and treatment among other issues. The HDG will be informed as soon as a specific proposal is received from the Iranian side as regards cooperation in the field of drugs.

### **5. Preparation for the EU-US dialogue on drugs**

The Presidency informed the meeting about the preparations for the forthcoming EU-US dialogue on drugs to be held as a videoconference on 10 February 2017.

### **6. Information on the EU-Brazil dialogue on drugs**

The Presidency informed the meeting that the EU-Brazil dialogue on drugs will be held on 16 March 2017 in Vienna, in the margins of the 60th CND session.

## 7. AOB

- *update by the Presidency on the proceedings as regards new psychoactive substances MDMB-CHMICA and acryloylfentanyl*

The Presidency informed the meeting that on 23 January 2017 the Council should request to conduct a risk assessment on the new psychoactive substance acryloylfentanyl and that the European Parliament intended to discuss the proposal to subject the new psychoactive substance MDMB-CHMICA to control measures at its plenary session in mid-February, after which the Council will take the decision.

---